CKMT2

CKMT2 (sarcomeric mitochondrial creatine kinase 2) is a mitochondrial protein implicated in muscle energy homeostasis, mapped to chromosome 5q13.3 distal to the spinal muscular atrophy locus (PMID:8276398). In a mouse model of acute myocardial infarction, CKMT2 protein is released into plasma specifically following reperfused — but not non-reperfused — injury, with circulating levels tracking infarct size and impaired left ventricular function, identifying it as a mitochondrial protein liberated upon reperfusion-specific cardiac damage (PMID:39457679). Beyond chromosomal localization and this injury-release phenotype, the enzymatic and signaling mechanisms of CKMT2 have not been characterized in the available corpus; lower-confidence findings link it to a putative ESRRG–PERM1–CKMT2 axis in genioglossal muscle and to control of myoblast proliferation and differentiation, but neither has been placed mechanistically.

1. 1993 Medium

   Establishing the genomic position of CKMT2 was the first step toward distinguishing it from neighboring disease loci on chromosome 5q.

   Evidence FISH of YAC clones with genetic mapping in CEPH families

   PMID:8276398

   Open questions at the time

   • No functional or enzymatic characterization
   • Does not address tissue expression or regulation
2. 2022 Low

   CKMT2 was placed in a candidate hormone-responsive regulatory context, addressing whether its abundance tracks muscle contractile dysfunction.

   Evidence Western blotting in an ovariectomized rat OSAHS model with estrogen treatment groups

   PMID:35623593

   Open questions at the time

   • Single method (western blot), no direct interrogation of CKMT2 function
   • Co-regulation with ESRRG and PERM1 is correlative, not a demonstrated physical or signaling axis
   • Direction of causality unestablished
3. 2024 Medium

   It was unknown whether CKMT2 could serve as a damage-specific marker; this work showed its plasma release is selective for reperfusion injury and correlates with cardiac dysfunction.

   Evidence Untargeted mass spectrometry plus ELISA validation of plasma in a mouse reperfused vs. non-reperfused AMI model, with echocardiography and TTC staining

   PMID:39457679

   Open questions at the time

   • Mechanism of release upon reperfusion not defined
   • Whether release is cause or consequence of dysfunction unresolved
   • Human relevance not established
4. 2025 Low

   Direct perturbation tested whether CKMT2 actively regulates muscle cell behavior rather than merely marking it, showing it drives myoblast proliferation and differentiation.

   Evidence Gain- and loss-of-function (overexpression and knockdown) in duck myoblasts with proliferation and myotube differentiation readouts

   PMID:41463801

   Open questions at the time

   • Non-human avian system only
   • No mechanistic pathway placement beyond phenotypic readout
   • No link to its mitochondrial creatine kinase enzymatic activity

• The enzymatic mechanism, substrates, interaction partners, and the molecular basis for reperfusion-specific release of CKMT2 remain undefined.
• No biochemical reconstitution of catalytic activity in the corpus
• No validated direct protein partners
• Human functional data absent